Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Research & Development (2016 - 2025)

Historic Research & Development for Abvc Biopharma (ABVC) over the last 10 years, with Q3 2025 value amounting to $29890.0.

  • Abvc Biopharma's Research & Development fell 2097.82% to $29890.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $124007.0, marking a year-over-year decrease of 4349.89%. This contributed to the annual value of $179272.0 for FY2024, which is 8313.39% down from last year.
  • As of Q3 2025, Abvc Biopharma's Research & Development stood at $29890.0, which was down 2097.82% from $33276.0 recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Research & Development peaked at $1.5 million during Q4 2022, and registered a low of $28861.0 during Q1 2025.
  • For the 5-year period, Abvc Biopharma's Research & Development averaged around $264814.6, with its median value being $141310.0 (2023).
  • Its Research & Development has fluctuated over the past 5 years, first surged by 47488.74% in 2022, then tumbled by 9517.41% in 2023.
  • Over the past 5 years, Abvc Biopharma's Research & Development (Quarter) stood at $260188.0 in 2021, then soared by 474.89% to $1.5 million in 2022, then tumbled by 95.17% to $72185.0 in 2023, then plummeted by 55.7% to $31980.0 in 2024, then decreased by 6.54% to $29890.0 in 2025.
  • Its Research & Development stands at $29890.0 for Q3 2025, versus $33276.0 for Q2 2025 and $28861.0 for Q1 2025.